{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    14,
    15,
    16,
    17,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective - Induction",
        "text": "To evaluate the efficacy of intravenous (IV) ustekinumab in inducing clinical remission in subjects with moderately to severely active UC.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Safety Objective - Induction",
        "text": "To evaluate the safety of IV ustekinumab in subjects with moderately to severely active UC.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective - Endoscopic Healing (Induction)",
        "text": "To evaluate the efficacy of IV ustekinumab in inducing endoscopic healing (ie, improvement in the endoscopic appearance of the mucosa) in subjects with moderately to severely active UC.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective - Clinical Response (Induction)",
        "text": "To evaluate the efficacy of IV ustekinumab in inducing clinical response in subjects with moderately to severely active UC.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective - Quality of Life (Induction)",
        "text": "To evaluate the impact of IV ustekinumab on disease-specific health-related quality of life.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Primary Efficacy Objective - Maintenance",
        "text": "To evaluate clinical remission for SC maintenance regimens of ustekinumab in subjects with moderately to severely active UC induced into clinical response with ustekinumab.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Efficacy Objective - Maintenance of Clinical Response",
        "text": "To evaluate the efficacy of ustekinumab in maintaining clinical response in subjects induced into clinical response with ustekinumab.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Efficacy Objective - Endoscopic Healing (Maintenance)",
        "text": "To evaluate endoscopic healing (ie, improvement in the endoscopic appearance of the mucosa) in subjects induced into clinical response with ustekinumab.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Secondary Efficacy Objective - Corticosteroid-free Remission",
        "text": "To evaluate the efficacy of ustekinumab in achieving corticosteroid-free clinical remission in subjects induced into clinical response with ustekinumab.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Secondary Efficacy Objective - Maintenance of Clinical Remission",
        "text": "To evaluate the efficacy of ustekinumab in maintaining clinical remission in subjects induced into clinical remission with ustekinumab.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective - Bristol Stool Form Scale",
        "text": "To evaluate the performance of the Bristol Stool Form Scale score in the induction study.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Induction Endpoint",
        "text": "Clinical remission at Week 8",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Major Secondary Induction Endpoint 1",
        "text": "Endoscopic healing at Week 8",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Major Secondary Induction Endpoint 2",
        "text": "Clinical response at Week 8",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Major Secondary Induction Endpoint 3",
        "text": "Change from induction baseline in the total score of the IBDQ at Week 8",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_5",
        "name": "Primary Maintenance Endpoint",
        "text": "Clinical remission at Week 44",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Major Secondary Maintenance Endpoint 1",
        "text": "Maintenance of clinical response through Week 44",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Major Secondary Maintenance Endpoint 2",
        "text": "Endoscopic healing at Week 44",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Major Secondary Maintenance Endpoint 3",
        "text": "Clinical remission and not receiving concomitant corticosteroids at Week 44",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Major Secondary Maintenance Endpoint 4",
        "text": "Maintenance of clinical remission through Week 44 among the subjects who had achieved clinical remission at maintenance baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "Safety Endpoints",
        "text": "Adverse events; clinical laboratory tests (chemistry and hematology); vital signs and physical examinations; a screening electrocardiogram; allergic reactions, infusion reactions and injection site reactions; and early detection of active tuberculosis.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Endpoint - Bristol Stool",
        "text": "Average Bristol Stool Form Scale score over time in induction.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Induction Efficacy Estimand (Global)",
        "populationSummary": "Adults with moderately to severely active UC (Mayo score 6-12) who failed conventional or biologic therapy Summary measure: Difference in proportions (CMH chi-square test).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study agent before Week 8",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Rescue medication",
            "text": "Initiation or increase in dose of UC medications (corticosteroids, 5-ASAs, immunomodulators) during induction",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ustekinumab 130 mg IV or ~6 mg/kg IV vs Placebo IV",
        "analysisPopulation": "Adults with moderately to severely active UC (Mayo score 6-12) who failed conventional or biologic therapy",
        "variableOfInterest": "Clinical remission at Week 8 (Mayo score ≤2, no subscore >1)",
        "summaryMeasure": "Difference in proportions (CMH chi-square test)"
      },
      {
        "id": "est_2",
        "name": "Primary Maintenance Efficacy Estimand",
        "populationSummary": "Subjects in clinical response to IV ustekinumab induction (Primary Population) Summary measure: Difference in proportions (CMH chi-square test).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_5",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Clinical Flare / Loss of Response",
            "text": "Subject meets criteria for clinical flare or loss of response before Week 44",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Corticosteroid use",
            "text": "Failure to successfully taper or re-initiation of corticosteroids",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ustekinumab 90 mg SC q8w or q12w vs Placebo SC",
        "analysisPopulation": "Subjects in clinical response to IV ustekinumab induction (Primary Population)",
        "variableOfInterest": "Clinical remission at Week 44",
        "summaryMeasure": "Difference in proportions (CMH chi-square test)"
      },
      {
        "id": "est_3",
        "name": "Major Secondary Maintenance Estimand (Corticosteroid-free)",
        "populationSummary": "Subjects in clinical response to IV ustekinumab induction Summary measure: Difference in proportions (CMH chi-square test).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_8",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of SC study agent",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ustekinumab 90 mg SC q8w or q12w vs Placebo SC",
        "analysisPopulation": "Subjects in clinical response to IV ustekinumab induction",
        "variableOfInterest": "Clinical remission and not receiving concomitant corticosteroids at Week 44",
        "summaryMeasure": "Difference in proportions (CMH chi-square test)"
      }
    ],
    "summary": {
      "primaryObjectives": 3,
      "secondaryObjectives": 7,
      "exploratoryObjectives": 1,
      "totalEndpoints": 11,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective - Induction",
        "text": "To evaluate the efficacy of intravenous (IV) ustekinumab in inducing clinical remission in subjects with moderately to severely active UC.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Safety Objective - Induction",
        "text": "To evaluate the safety of IV ustekinumab in subjects with moderately to severely active UC.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective - Endoscopic Healing (Induction)",
        "text": "To evaluate the efficacy of IV ustekinumab in inducing endoscopic healing (ie, improvement in the endoscopic appearance of the mucosa) in subjects with moderately to severely active UC.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective - Clinical Response (Induction)",
        "text": "To evaluate the efficacy of IV ustekinumab in inducing clinical response in subjects with moderately to severely active UC.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective - Quality of Life (Induction)",
        "text": "To evaluate the impact of IV ustekinumab on disease-specific health-related quality of life.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Primary Efficacy Objective - Maintenance",
        "text": "To evaluate clinical remission for SC maintenance regimens of ustekinumab in subjects with moderately to severely active UC induced into clinical response with ustekinumab.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Efficacy Objective - Maintenance of Clinical Response",
        "text": "To evaluate the efficacy of ustekinumab in maintaining clinical response in subjects induced into clinical response with ustekinumab.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Efficacy Objective - Endoscopic Healing (Maintenance)",
        "text": "To evaluate endoscopic healing (ie, improvement in the endoscopic appearance of the mucosa) in subjects induced into clinical response with ustekinumab.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Secondary Efficacy Objective - Corticosteroid-free Remission",
        "text": "To evaluate the efficacy of ustekinumab in achieving corticosteroid-free clinical remission in subjects induced into clinical response with ustekinumab.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Secondary Efficacy Objective - Maintenance of Clinical Remission",
        "text": "To evaluate the efficacy of ustekinumab in maintaining clinical remission in subjects induced into clinical remission with ustekinumab.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective - Bristol Stool Form Scale",
        "text": "To evaluate the performance of the Bristol Stool Form Scale score in the induction study.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Induction Endpoint",
        "text": "Clinical remission at Week 8",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Major Secondary Induction Endpoint 1",
        "text": "Endoscopic healing at Week 8",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Major Secondary Induction Endpoint 2",
        "text": "Clinical response at Week 8",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Major Secondary Induction Endpoint 3",
        "text": "Change from induction baseline in the total score of the IBDQ at Week 8",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_5",
        "name": "Primary Maintenance Endpoint",
        "text": "Clinical remission at Week 44",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Major Secondary Maintenance Endpoint 1",
        "text": "Maintenance of clinical response through Week 44",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Major Secondary Maintenance Endpoint 2",
        "text": "Endoscopic healing at Week 44",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Major Secondary Maintenance Endpoint 3",
        "text": "Clinical remission and not receiving concomitant corticosteroids at Week 44",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Major Secondary Maintenance Endpoint 4",
        "text": "Maintenance of clinical remission through Week 44 among the subjects who had achieved clinical remission at maintenance baseline",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "Safety Endpoints",
        "text": "Adverse events; clinical laboratory tests (chemistry and hematology); vital signs and physical examinations; a screening electrocardiogram; allergic reactions, infusion reactions and injection site reactions; and early detection of active tuberculosis.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Endpoint - Bristol Stool",
        "text": "Average Bristol Stool Form Scale score over time in induction.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Induction Efficacy Estimand (Global)",
        "populationSummary": "Adults with moderately to severely active UC (Mayo score 6-12) who failed conventional or biologic therapy Summary measure: Difference in proportions (CMH chi-square test).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study agent before Week 8",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Rescue medication",
            "text": "Initiation or increase in dose of UC medications (corticosteroids, 5-ASAs, immunomodulators) during induction",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ustekinumab 130 mg IV or ~6 mg/kg IV vs Placebo IV",
        "analysisPopulation": "Adults with moderately to severely active UC (Mayo score 6-12) who failed conventional or biologic therapy",
        "variableOfInterest": "Clinical remission at Week 8 (Mayo score ≤2, no subscore >1)",
        "summaryMeasure": "Difference in proportions (CMH chi-square test)"
      },
      {
        "id": "est_2",
        "name": "Primary Maintenance Efficacy Estimand",
        "populationSummary": "Subjects in clinical response to IV ustekinumab induction (Primary Population) Summary measure: Difference in proportions (CMH chi-square test).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_5",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Clinical Flare / Loss of Response",
            "text": "Subject meets criteria for clinical flare or loss of response before Week 44",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Corticosteroid use",
            "text": "Failure to successfully taper or re-initiation of corticosteroids",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ustekinumab 90 mg SC q8w or q12w vs Placebo SC",
        "analysisPopulation": "Subjects in clinical response to IV ustekinumab induction (Primary Population)",
        "variableOfInterest": "Clinical remission at Week 44",
        "summaryMeasure": "Difference in proportions (CMH chi-square test)"
      },
      {
        "id": "est_3",
        "name": "Major Secondary Maintenance Estimand (Corticosteroid-free)",
        "populationSummary": "Subjects in clinical response to IV ustekinumab induction Summary measure: Difference in proportions (CMH chi-square test).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_8",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of SC study agent",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Ustekinumab 90 mg SC q8w or q12w vs Placebo SC",
        "analysisPopulation": "Subjects in clinical response to IV ustekinumab induction",
        "variableOfInterest": "Clinical remission and not receiving concomitant corticosteroids at Week 44",
        "summaryMeasure": "Difference in proportions (CMH chi-square test)"
      }
    ]
  }
}